# US 2019/0314555 A1 · Supramolecular Alginate Materials for Biomedical Applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314555 A1
- Document ID: US20190314555A1
- Status: Published application
- Kind: A1
- Application number: 16/381,718
- Filed: 2019-04-11
- Published: 2019-10-17
- Earliest claimed: 2018-04-11
- Assignees: University of Vermont and State Agricultural College
- Applicants: University of Vermont and State Agricultural College
- Inventors: Rachael A. Oldinski; Jennifer N. Etter
- Web page: https://patentgrep.com/patent/US20190314555A1

## CPC

- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/52: Hydrogels or hydrocolloids
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61L 27/20: Polysaccharides
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 2300/414: Growth factors
- A61L 2300/62: Encapsulated active agents, e.g. emulsified droplets
- A61L 2300/64: Animal cells
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the unexpected discovery of novel hydrogel formulations that allow for the encapsulation and delivery of living cells and/or drugs to a subject in need thereof. In certain embodiments, the hydrogel compositions of the invention comprise bound bioactive molecules that promote long-term cell viability and allows for the development of vasculature. The invention further provides methods of delivering viable cells and/or drugs to a subject comprising administering the compositions of the invention to the subject in need thereof.

## Claims

### Claim 1

A hydrogel composition comprising:
at least one selected from alginate (Alg) and methacrylated alginate (Alg-MA);
β-cyclodextrin (β-CD); and
at least one additional component selected from the group consisting of heparin (hep) and arginylglycylaspartic acid (RGD);
wherein the β-cyclodextrin (β-CD) and the at least one additional component are each covalently bound to the alginate or methacrylated alginate.

### Claim 2 (depends on 1)

The hydrogel of claim 1, further comprising at least one crosslinking component selected from the group consisting of polypropylene glycol (PPG), polyethylene glycol (PEG), polyethylene oxide (PEO), PEG-b-PPG-b-PEG copolymers, PEO-b-PPG-b-PEO copolymers, agarose, amylase, amylpectin, cellularose, chitosan, collagen, fibrin, gelatin, glycogenhyaluronic acid, poly(acrylamide), poly(β-aminoester), poly(caprolactone), matrigel, multi-arm polyethylene glycol, poly-hydroxyethyl acrylate, poly(hydroxyethyl methacrylate), poly(N-isopropylacrylamide), poly(glycolic acid), poly(lactic acid), poly(lactic acid-glycolic acid), oligo(poly(ethylene glycol)fumarate), poly(vinyl alcohol), poly(vinyl acid), 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC), and N-hydroxysuccinimide (NETS).

### Claim 3 (depends on 2)

The hydrogel of claim 2, wherein the alginate and β-cyclodextrin forms a supramolecular complex with the at least one crosslinking component.

### Claim 4 (depends on 1)

The hydrogel of claim 1, further comprising living cells.

### Claim 5 (depends on 4)

The hydrogel of claim 4, wherein the living cells are encapsulated within the hydrogel composition.

### Claim 6 (depends on 4)

The hydrogel of claim 4, wherein the living cells are eukaryotic cells.

### Claim 7 (depends on 4)

The hydrogel of claim 4, wherein the living cells are progenitor cells.

### Claim 8 (depends on 7)

The hydrogel of claim 7, wherein the living cells are human mesenchymal stem cells.

### Claim 9 (depends on 1)

The hydrogel of claim 1, further comprising at least one pharmaceutically active compound.

### Claim 10 (depends on 9)

The hydrogel of claim 9, wherein the at least one pharmaceutically active compound is encapsulated within the hydrogel composition.

### Claim 11 (depends on 9)

The hydrogel of claim 9, wherein the at least one pharmaceutically active compound is non-covalently bound to the hydrogel composition through a guest-host interaction with the a β-cyclodextrin moiety.

### Claim 12 (depends on 1)

The hydrogel of claim 1, further comprising at least one biological factor.

### Claim 13 (depends on 12)

The hydrogel of claim 12, wherein the at least one biological factor modifies one or more cellular functions selected from the group consisting of cell growth, cell viability, cell adhesion, tissue adhesion, and progenitor cell differentiation.

### Claim 14 (depends on 12)

The hydrogel of claim 12, wherein the at least one biological factor is a heparin or RGD binding protein.

### Claim 15 (depends on 12)

The hydrogel of claim 12, wherein the at least one biological factor is selected from the group consisting of epidermal growth factor (EGF), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF-β), and tissue inhibitors of metalloproteinases (TIMP).

### Claim 16 (depends on 12)

The hydrogel of claim 12, wherein the at least one biological factor is non-covalently bound to the hydrogel composition through a guest-host interaction with the a β-cyclodextrin moiety.

### Claim 17 (depends on 1)

The hydrogel of claim 1, wherein the hydrogel composition is in the form of a microsphere composition.

### Claim 18 (depends on 17)

The hydrogel of claim 17, wherein the microsphere composition comprises monodisperse microspheres.

### Claim 19 (depends on 17)

The hydrogel of claim 17, wherein the microsphere composition comprises microspheres having a diameter of about 500 nm to about 80 μm.

### Claim 20 (depends on 1)

The hydrogel of claim 1, wherein the hydrogel composition is formulated as part of a pharmaceutical composition.

### Claim 21 (depends on 20)

The hydrogel of claim 20, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.

### Claim 22 (depends on 20)

The hydrogel of claim 20, wherein the pharmaceutical composition is in a form selected from the group consisting of a cream, liquid, gel, spray, ointment, 3-D scaffold, powder, patch and graft.

### Claim 23

A method of delivering viable living cells to a subject, the method comprising administering to the subject a hydrogel composition comprising alginate, β-cyclodextrin, living cells and at least one additional component selected from the group consisting of heparin and RGD wherein the at least one additional component is covalently bound to the alginate and wherein the alginate is optionally methacrylated.

### Claim 24 (depends on 23)

The method of claim 23, wherein the living cells are encapsulated within the hydrogel composition.

### Claim 25 (depends on 23)

The method of claim 23, wherein the living cells are eukaryotic cells.

### Claim 26 (depends on 23)

The method of claim 23, wherein the living cells are progenitor cells.

### Claim 27 (depends on 23)

The method of claim 23, wherein the living cells are human mesenchymal stem cells.

### Claim 28 (depends on 23)

The method of claim 23, wherein the method treats at least one disease or disorder in the subject selected from the group consisting of immune-mediated diseases, skeletal tissue injury, of immune-mediated diseases, skeletal/cranial tissue injury, skeletal diseases, skin wounds, internal organ wounds, cancers, inflammatory diseases, infections, and chronic wounds.

### Claim 29

A method of treating a wound in a subject in need thereof, the method comprising contacting the wound with a hydrogel composition comprising alginate, β-cyclodextrin modified alginate, living cells and at least one additional component selected from the group consisting of heparin and RGD wherein the at least one additional component is covalently bound to the alginate and wherein the alginate is optionally methacrylated.

### Claim 30 (depends on 29)

The method of claim 29, wherein the living cells are encapsulated within the hydrogel composition.

### Claim 31 (depends on 29)

The method of claim 29, wherein the living cells are eukaryotic cells.

### Claim 32 (depends on 29)

The method of claim 29, wherein the living cells are progenitor cells.

### Claim 33 (depends on 29)

The method of claim 29, wherein the living cells are human mesenchymal stem cells.

### Claim 34 (depends on 29)

The method of claim 29, wherein the hydrogel composition is in the form of cream, liquid, gel, spray, ointment, 3-D scaffold, powder, patch or graft.

### Claim 35 (depends on 29)

The method of claim 29, wherein the hydrogel composition is disposed on the surface of a bandage, patch, secondary hydrogel scaffold or graft.
